once daily
Showing 1 - 25 of >10,000
Wilson's Disease Trial in London (900mg TETA 4HCl Once Daily Formulation, 900mg TETA 4HCl Cuprior®)
Not yet recruiting
- Wilson's Disease
- 900mg TETA 4HCl Once Daily Formulation
- 900mg TETA 4HCl Cuprior®
-
London, United KingdomRichmond Pharmacology Ltd
Nov 7, 2023
Hypercholesterolemia Trial in Japan (K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily))
Recruiting
- Hypercholesterolemia
- K-877 0.2 mg/day (once daily)
- +2 more
-
Aichi, Japan
- +14 more
Jun 20, 2023
Garden of Life Once Daily Women's Probiotic: Vaginal pH and
Active, not recruiting
- Vaginal Health
- Once Daily Women's Probiotic
- Placebo
-
Wellington, FloridaSyzygy Research Solutions
Aug 1, 2022
Acne Vulgaris Trial in Karachi (Clindamycin and Dapsone gel for 03 months)
Completed
- Acne Vulgaris
- Clindamycin and Dapsone gel for 03 months
-
Karachi, Sindh, PakistanJPMC
Jun 23, 2023
Lupus Nephritis Trial in Alexandria (Dapagliflozin 10mg Tab orally once daily)
Not yet recruiting
- Lupus Nephritis
- Dapagliflozin 10mg Tab orally once daily
-
Alexandria, EgyptAin Shams University
Oct 27, 2023
Lung Cancer Trial in Manchester (Once daily radiotherapy, Twice daily radiotherapy)
Completed
- Lung Cancer
- Once daily radiotherapy
- Twice daily radiotherapy
-
Manchester, United KingdomThe Christie NHS Foundation Trust
Sep 5, 2022
Healthy Volunteers - Liver Diseases Trial in Watford (NNC0560-0004, Placebo (NNC0560-0004))
Recruiting
- Healthy Volunteers - Liver Diseases
- NNC0560-0004
- Placebo (NNC0560-0004)
-
Watford, Middlesex, United KingdomNovo Nordisk Investigational Site
Nov 14, 2023
MDD Trial in Tokyo (OPC-64005 20 mg , Once-daily, OPC-64005 10 mg , Once-daily, Placebo, Once-daily)
Completed
- Major Depressive Disorder
- OPC-64005 20 mg , Once-daily
- +2 more
-
Tokyo, JapanMedical Corporation Jisenkai Himorogi Psychiatric Institute
Sep 7, 2022
Kidney Transplantation, Pancreas Transplantation, Diabetes Trial in Nantes (Tacrolimus and Tacrolimus Extended Release Oral
Recruiting
- Kidney Transplantation
- +2 more
- Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]
-
Nantes, FranceNantes University Hospital
Aug 10, 2022
Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group
Not yet recruiting
- Neurofibromatosis 1
- +2 more
- Test group (Group A): FCN-159 8 mg, orally, once daily;
- Control group (Group B): Placebo, orally, once daily;
- (no location specified)
Jun 16, 2023
Intermittent Claudication Trial in Springfield (Cilostazol Tablet 100 mg, PMR Tablet 135 mg)
Recruiting
- Intermittent Claudication
- Cilostazol Tablet 100 mg
- PMR Tablet 135 mg
-
Springfield, MissouriBio-Kinetic Clinical Applications, LLC
Aug 1, 2022
Renal Failure, Renal Insufficiency, Renal Disease Trial in Dresden (Advagraf)
Active, not recruiting
- Renal Failure
- +3 more
-
Dresden, GermanyUniversitätsklinikum Carl Gustav Carus
Aug 2, 2022
Allergic Conjunctivitis Trial in Andover (olopatadine HCl ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale)
Recruiting
- Allergic Conjunctivitis
- olopatadine hydrochloride ophthalmic solution 0.7%)
- +3 more
-
Andover, MassachusettsAndover Eye Associates
Jul 18, 2022
End Stage Renal Disease, Rejection of Renal Transplant Trial in Chicago (Tacrolimus, Tacrolimus Extended Release Oral Tablet
Completed
- End Stage Renal Disease
- Rejection of Renal Transplant
- Tacrolimus
- Tacrolimus Extended Release Oral Tablet [Envarsus]
-
Chicago, IllinoisNorthwestern University
Jan 12, 2023
Dyslipidemias Trial in Japan (K-877 ER 0.2 mg/day morning administration (once daily), K-877 ER 0.2 mg/day evening
Completed
- Dyslipidemias
- K-877 ER 0.2 mg/day morning administration (once daily)
- K-877 ER 0.2 mg/day evening administration (once daily)
-
Fukuoka, Japan
- +13 more
Aug 8, 2022
Hepatic Hemangioma, Liver Cancer, Hepatolithiasis Trial in Chongqing (Sham-Remote Ischemic Conditioning, Remote Ischemic
Recruiting
- Hepatic Hemangioma
- +3 more
- Sham-Remote Ischemic Conditioning
- +2 more
-
Chongqing, ChinaThe Second Affiliated Hospital, Chongqing Medical University
Nov 8, 2023
